Chronic hepatitis B
Conditions
Interventions
Sponsors
Hangzhou Xixi Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients with previous history of hepatitis B or HBsAg positive for more than six months, HBsAg and/or HBV-DNA are still positive; (2) Patients who meet the antiviral indications in the guidelines or are taking entecavir dispersible tablets Patients treated with virus; (3) aged 18 to 65 years old; (4) patients with TCM syndromes of liver spleen deficiency and dampness and heat syndrome; (5) signed informed consent.
Exclusion criteria
Exclusion criteria: (1) patients with cirrhosis; (2) patients with liver cancer; (3) acute and chronic hepatitis with non-HBV hepadnavirus infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Genetic metabolic liver disease, drug or toxic hepatitis, alcoholic liver disease; (4) pregnant or lactating women and women who plan to be pregnant during the study period; (5) those who are allergic to the test drug; (6) have mental disorders can not cooperate Patients in this study, or patients with unstable epilepsy; (7) Patients with systemic diseases such as severe heart, brain, lung, kidney, and hematopoiesis; (8) Alcoholism or other unsuitable drug test observers, or In combination with treatment, it is difficult to make a definitive evaluation of the effectiveness and safety of the drug; (9) Other circumstances that the investigator believes are not suitable for enrollment.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| HBV-DNA conversion rate;HBsAg negative rate;HBeAg serological conversion rate;liver function;Symptoms;signs;The thickness of spleen; | — |
Primary
| Measure | Time frame |
|---|---|
| Annual incidence of cirrhosis; | — |
Countries
China
Contacts
Public ContactShourong Liu
Hangzhou Xixi Hospital
Outcome results
None listed